Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Patients with Advanced Urinary Tract Cancer
October 16, 2012|Oncology Practice
Author and Disclosure Information
Objectives: This randomized placebo-controlled phase III trial asks whether adding bevacizumab (Avastin) to a gemcitabine (Gemzar) and cisplatin regimen can improve overall survival.
Key entry or exclusion criteria: Patients cannot be a candidate for potentially curative surgery or radiotherapy.
Locations: 497 sites.
Goal: 500 patients.
Study sponsor: Cancer and Leukemia Group B in collaboration with the National Cancer Institute.
Link for more information: clinicaltrials.gov/ct2/show/NCT00942331
NIH clinical trials identifier: NCT00942331